MX2019007325A - Composiciones y metodos para tratar la sobrecarga de hierro. - Google Patents
Composiciones y metodos para tratar la sobrecarga de hierro.Info
- Publication number
- MX2019007325A MX2019007325A MX2019007325A MX2019007325A MX2019007325A MX 2019007325 A MX2019007325 A MX 2019007325A MX 2019007325 A MX2019007325 A MX 2019007325A MX 2019007325 A MX2019007325 A MX 2019007325A MX 2019007325 A MX2019007325 A MX 2019007325A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- iron overload
- treating iron
- hepcidin
- Prior art date
Links
- 206010065973 Iron Overload Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 abstract 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
- 229940066919 hepcidin Drugs 0.000 abstract 2
- 102000018511 hepcidin Human genes 0.000 abstract 1
- 108060003558 hepcidin Proteins 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000009919 sequestration Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Financial Or Insurance-Related Operations Such As Payment And Settlement (AREA)
Abstract
La presente descripción se refiere al uso de hepcidina, mini-hepcidina o un análogo de hepcidina en métodos terapéuticos para el tratamiento y/o prevención de la sobrecarga de hierro adquirida u otras afecciones para las cuales es útil la redistribución o el secuestro de hierro.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762447710P | 2017-01-18 | 2017-01-18 | |
| US201762454322P | 2017-02-03 | 2017-02-03 | |
| US201762554115P | 2017-09-05 | 2017-09-05 | |
| PCT/US2018/014241 WO2018136636A1 (en) | 2017-01-18 | 2018-01-18 | Compositions and methods for treating iron overload |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019007325A true MX2019007325A (es) | 2019-09-02 |
Family
ID=62908242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019007325A MX2019007325A (es) | 2017-01-18 | 2018-01-18 | Composiciones y metodos para tratar la sobrecarga de hierro. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190336583A1 (es) |
| EP (1) | EP3570873A1 (es) |
| JP (1) | JP2020504160A (es) |
| CN (1) | CN110520147A (es) |
| AU (1) | AU2018210166A1 (es) |
| BR (1) | BR112019014524A2 (es) |
| CA (1) | CA3049977A1 (es) |
| IL (1) | IL267908A (es) |
| MA (1) | MA47322A (es) |
| MX (1) | MX2019007325A (es) |
| PH (1) | PH12019501631A1 (es) |
| SG (1) | SG11201906001RA (es) |
| WO (1) | WO2018136636A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020317631B2 (en) * | 2019-07-19 | 2025-09-18 | Vifor (International) Ag | Ferroportin-inhibitors for the use in the prevention and treatment of kidney injuries |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011250940B2 (en) * | 2010-05-10 | 2016-02-25 | Austin Health | Markers for acute kidney injury |
| CN105451755B (zh) * | 2013-03-15 | 2020-10-13 | 领导医疗有限公司 | 铁调素类似物和其用途 |
| US9981012B2 (en) * | 2013-09-20 | 2018-05-29 | University Of Virginia Patent Foundation | Compositions and methods for protecting the kidney from ischemia reperfusion injury |
| MX2018008299A (es) * | 2016-01-08 | 2018-09-21 | La Jolla Pharma Co | Metodos para administrar hepcidina. |
-
2018
- 2018-01-18 SG SG11201906001RA patent/SG11201906001RA/en unknown
- 2018-01-18 US US16/478,998 patent/US20190336583A1/en not_active Abandoned
- 2018-01-18 AU AU2018210166A patent/AU2018210166A1/en not_active Abandoned
- 2018-01-18 WO PCT/US2018/014241 patent/WO2018136636A1/en not_active Ceased
- 2018-01-18 CN CN201880014845.2A patent/CN110520147A/zh active Pending
- 2018-01-18 EP EP18742291.0A patent/EP3570873A1/en not_active Withdrawn
- 2018-01-18 MA MA047322A patent/MA47322A/fr unknown
- 2018-01-18 JP JP2019538184A patent/JP2020504160A/ja active Pending
- 2018-01-18 CA CA3049977A patent/CA3049977A1/en not_active Abandoned
- 2018-01-18 BR BR112019014524-9A patent/BR112019014524A2/pt not_active Application Discontinuation
- 2018-01-18 MX MX2019007325A patent/MX2019007325A/es unknown
-
2019
- 2019-07-08 IL IL267908A patent/IL267908A/en unknown
- 2019-07-12 PH PH12019501631A patent/PH12019501631A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018210166A1 (en) | 2019-07-25 |
| IL267908A (en) | 2019-09-26 |
| MA47322A (fr) | 2019-11-27 |
| US20190336583A1 (en) | 2019-11-07 |
| PH12019501631A1 (en) | 2020-03-09 |
| CN110520147A (zh) | 2019-11-29 |
| CA3049977A1 (en) | 2018-07-26 |
| EP3570873A1 (en) | 2019-11-27 |
| WO2018136636A1 (en) | 2018-07-26 |
| JP2020504160A (ja) | 2020-02-06 |
| SG11201906001RA (en) | 2019-08-27 |
| BR112019014524A2 (pt) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023009483A (es) | Anticuerpos monoclonales para usarse para el tratamiento de sinucleinopatia. | |
| MX2018005600A (es) | Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello. | |
| JOP20180008A1 (ar) | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| MX2017005282A (es) | Nuevos compuestos como inhibidores de la cinasa inductora de nf-kb (nik). | |
| MX2018002962A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la produccion de especies de oxigeno reactivo (eor) mitocondrial. | |
| PH12021551455A1 (en) | Jak1 pathway inhibitors for the treatment of gastrointestinal disease | |
| MX2017005285A (es) | Nuevos derivados de tienopirimidina en calidad de inhibidores de la cinasa inductora de nf-kb (nik). | |
| MX371152B (es) | Nuevos derivados de pirazolopirimidina como inhibidores de la cinasa inductora de nf-kb (nk). | |
| SA519410324B1 (ar) | صياغات رش إيبينيفرين | |
| MX371150B (es) | NUEVOS DERIVADOS DE PIRAZOL EN CALIDAD DE INHIBIDORES DE LA CINASA INDUCTORA DE NF-kB (NIK). | |
| MX2017015012A (es) | Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné. | |
| MX2023010501A (es) | Profarmacos de dantroleno y metodos de su uso. | |
| EA201892297A1 (ru) | Способы лечения холестатических и фибротических заболеваний | |
| EA201990930A1 (ru) | Способы, композиции и режимы дозирования для лечения или профилактики связанных с интерфероном-гамма заболеваний | |
| PH12016502322B1 (en) | Compounds and methods for preventing or treating malaria | |
| MX2018009662A (es) | Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. | |
| MX2020001164A (es) | Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico. | |
| MX2020002147A (es) | Composiciones útiles para la mejora del dolor. | |
| EA201992532A1 (ru) | Композиции и способ для лечения депрессии | |
| PH12019501631A1 (en) | Compositions and methods for treating iron overload | |
| MX2019004179A (es) | Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer. | |
| MY182818A (en) | Compositions for the treatment of fibrosis and fibrosis-related conditions | |
| PH12019500180A1 (en) | Compositions for the treatment of pulmonary fibrosis | |
| GEAP202014778A (en) | Combination of trazodone and gabapentin for the treatmen |